Welcome to our dedicated page for Sanofi FR SEC filings (Ticker: SNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanofi (SNY) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ and EURONEXT. Sanofi files annual reports on Form 20-F and frequent Form 6-K current reports that incorporate press releases, financial statements, and transaction documents by reference. These filings help investors track Sanofi’s operations as an R&D driven, AI-powered biopharma company focused on medicines and vaccines in immunology, autoimmune disease, rare disease, diabetes, respiratory conditions, and other areas.
Recent 6-K filings referenced in the available data include current reports attaching press releases on product approvals and recommendations (such as Wayrilz for immune thrombocytopenia, Qfitlia and Cablivi approvals in China, and high-dose influenza vaccine data), clinical and regulatory updates for pipeline assets (including tolebrutinib and efdoralprin alfa), and corporate transactions such as the completed acquisition of Vicebio and the planned acquisition of Blueprint Medicines. Other 6-Ks describe debt offerings, including the issuance and pricing of multiple series of fixed and floating rate notes under an indenture, along with the related underwriting agreement and legal opinions.
Sanofi’s interim financial information is also furnished on Form 6-K, including unaudited condensed half-year consolidated financial statements prepared under IFRS. These documents discuss topics such as discontinued operations, joint ventures, contingent consideration, royalties, and financial instruments. Together, the filings provide a detailed view of Sanofi’s capital structure, financing activities, product pipeline progress, and geographic footprint.
On this page, Stock Titan surfaces Sanofi’s latest SEC filings as they are made available from EDGAR and applies AI-powered summaries to help explain the contents of lengthy documents. Users can quickly identify key points in 20-F annual reports, 6-K current reports, and related exhibits, and can review how clinical, regulatory, and financing events are reflected in Sanofi’s official disclosures.
Sanofi filed a Form 6-K to furnish two December 15, 2025 press releases related to its multiple sclerosis candidate tolebrutinib. One press release provides an update on the regulatory submission for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, and the other provides an update on tolebrutinib in primary progressive multiple sclerosis. Both press releases are incorporated into this report by reference.
Sanofi reports two key developments from December 2025. The company completed its acquisition of Vicebio, as described in a press release dated December 4, 2025.
A second press release dated December 11, 2025 reports that Sanofi’s medicines Qfitlia and Cablivi were approved in China, expanding care options for patients with rare diseases in that market.
Sanofi furnished a report summarizing two recent regulatory milestones. One press release describes a pivotal study of Dupixent in allergic fungal rhinosinusitis that met all primary and secondary endpoints and reduced signs and symptoms of the disease, and notes that a supplemental Biologics License Application has been accepted for FDA priority review. A second press release states that Teizeild has been recommended for European Union approval by the CHMP for patients with stage 2 type 1 diabetes.
Sanofi filed a Form 13F reporting its institutional holdings. The filing lists 9 holdings entries with a total reported market value of $260,361,143 (rounded to nearest dollar). The report is signed by Alexandra Roger, Head of Legal Corporate & Finance, and dated 11-04-2025.
Sanofi reported the issuance of multiple U.S. dollar notes on November 3, 2025, totaling $3,000,000,000 in principal. The company sold $500,000,000 floating rate notes due November 3, 2027, $500,000,000 floating rate notes due November 3, 2028, $400,000,000 fixed rate notes due November 3, 2027, $400,000,000 fixed rate notes due November 3, 2028, and $1,200,000,000 fixed rate notes due November 3, 2032.
The report is incorporated by reference into Sanofi’s Form F-3 (No. 333-278506). Exhibits include the underwriting agreement with Barclays Capital Inc., BNP Paribas Securities Corp., BofA Securities, Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, MUFG Securities Americas Inc., and Natixis Securities Americas LLC; an indenture with Deutsche Bank Trust Company Americas as trustee; form notes for each tranche; and legal opinions from Jones Day under French and New York law.
Sanofi (SNY) furnished a Form 6-K noting it has attached a press release dated October 22, 2025. The release reports that efdoralprin alfa met all primary and key secondary endpoints in a phase 2 study for alpha-1 antitrypsin deficiency (AATD) emphysema. This update signals a positive clinical milestone for the program and supports continued development based on the study’s predefined goals.
The filing itself provides no additional trial data beyond the headline result. Readers seeking design details, specific endpoints, or safety and efficacy metrics should refer to Exhibit 99.1, which contains the full press release.
Sanofi S.A. launched a primary debt offering of $500,000,000 floating rate notes due 2027, $500,000,000 floating rate notes due 2028, $400,000,000 3.750% notes due 2027, $400,000,000 3.800% notes due 2028, and $1,200,000,000 4.200% notes due 2032. Interest begins accruing on November 3, 2025.
The floating notes pay Compounded SOFR plus 0.460% (2027) or 0.540% (2028) with quarterly payments; fixed notes pay semiannually. Fixed tranches feature make‑whole redemption prior to defined par call dates, and par redemption thereafter; floaters are not redeemable before maturity except for tax events. The notes are unsecured, unsubordinated, not listed, and issued in $2,000 minimums.
Gross pricing reflected modest underwriting discounts, and net proceeds are approximately $2,986,198,000, intended for general corporate purposes.
Sanofi furnished a Form 6-K noting a press release titled “Sanofi successfully prices USD 3 billion of bond issue.” The filing indicates the company priced a USD 3 billion bond and includes the press release as Exhibit 99.1.
The press release is dated October 28, 2025, and is incorporated by reference in the submission.
Sanofi (SNY) filed a preliminary 424(b)(5) prospectus supplement to issue multiple tranches of unsecured, unsubordinated notes, including floating‑rate series tied to Compounded SOFR and fixed‑rate series. The notes rank equally with Sanofi’s other unsecured debt, are not subject to a sinking fund, and will not be listed on an exchange.
The floating‑rate notes reset quarterly at Compounded SOFR plus a margin and pay interest quarterly; the fixed‑rate notes pay interest semi‑annually. Interest begins accruing in 2025 with first payments in 2026. Optional redemption for fixed‑rate tranches includes a make‑whole call and a par call window, and all notes include tax redemption provisions. Minimum denominations are $2,000 and integral multiples of $1,000, delivered in book‑entry form through DTC, Euroclear and Clearstream. Sanofi intends to use net proceeds for general corporate purposes.
Sanofi furnished a Form 6‑K providing H1 2025 condensed consolidated results and updates. The company lost control of Opella on April 30, 2025; from May 1, 2025 OPAL JV Co is accounted for using the equity method. H1 operating cash flows reflect routine items, including income tax paid of €1,355 million, interest paid of €206 million, and interest received of €170 million.
Financing and liabilities were active across the period. As of June 30, 2025, current other bank borrowings included €4,535 million related to the US commercial paper program and €230 million related to the French program, while a financing cash‑flow line mainly comprised the US commercial paper program of €3,353 million (vs €6,060 million in H1 2024). Net debt metrics exclude lease liabilities of €1,776 million. The liability for royalties payable to Sobi on US Beyfortus net sales was €1,756 million, with nominal payments estimated at €1,027 million within one to five years and €2,293 million thereafter. The period included impairment losses of €210 million linked to R&D projects, a €17 million tax expense from Pillar Two, and an €88 million tax expense tied to the gain on the Opella deconsolidation.